What one share of PROCEPT BioRobotics holds
We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH.
PROCEPT BioRobotics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.99 |
|---|---|
| Profit | −$1.95 |
| Capex (buildings and equipment) | $0.19 |
| Free cash flow | −$1.51 |
| Cash and investments | $3.98 |
| Debt | $0.90 |
| Book value | $5.94 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $2.11 | −$14.47 | $0.06 | −$13.26 | — | −$38.81 |
| 2021 | $2.09 | −$3.63 | $0.04 | −$3.51 | — | — |
| 2022 | $1.69 | −$1.96 | $0.06 | −$1.87 | — | $4.40 |
| 2023 | $2.88 | −$2.24 | $0.53 | −$2.82 | — | $5.53 |
| 2024 | $4.31 | −$1.75 | $0.08 | −$1.99 | — | $7.35 |
| 2025 | $5.55 | −$1.72 | $0.17 | −$1.05 | — | $6.50 |
Common questions about PROCEPT BioRobotics
How much does one share of PROCEPT BioRobotics earn?
Over the last 12 months, PROCEPT BioRobotics lost $1.95 for each share on $5.99 of sales.
Does PROCEPT BioRobotics pay a dividend?
PROCEPT BioRobotics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is PROCEPT BioRobotics’s book value per share?
PROCEPT BioRobotics’s book value is $5.94 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of PROCEPT BioRobotics have?
Each share of PROCEPT BioRobotics has $3.98 of cash and investments and $0.90 of debt, as of June 30, 2026.
What is PROCEPT BioRobotics’s free cash flow per share?
−$1.51 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has PROCEPT BioRobotics bought back shares?
PROCEPT BioRobotics’s share count rose about 1416% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.